Trial Profile

A Phase 1 Study of LY3484356 in Chinese Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imlunestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

03 Mar 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
28 Aug 2024 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.
08 Jan 2024 Planned End Date changed from 30 Jan 2025 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com